Cargando…

Exogenous NADPH exerts a positive inotropic effect and enhances energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure

BACKGROUND: Therapies are urgently required to ameliorate pathological cardiac hypertrophy and enhance cardiac function in heart failure. Our preliminary experiments have demonstrated that exogenous NADPH exhibits a positive inotropic effect on isolated heart. This study aims to investigate the posi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Ke, Tang, Jie, Ling, Yue-Juan, Zhou, Ming, Yan, Xin-Xin, Xie, Yu, Zhu, Lu-Jia, Nirmala, Koju, Sun, Kang-Yun, Qin, Zheng-Hong, Sheng, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663691/ https://www.ncbi.nlm.nih.gov/pubmed/37950995 http://dx.doi.org/10.1016/j.ebiom.2023.104863

Ejemplares similares

Norepinephrine exerts an inotropic effect at the early phase of human septic shock
por: Hamzaoui, O, et al.
Publicado: (2015)

NADPH oxidase-4 promotes eccentric cardiac hypertrophy in response to volume overload
por: Schnelle, Moritz, et al.
Publicado: (2019)

SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity
por: Feng, Xiaojun, et al.
Publicado: (2020)

Vasopressor stays vasopressor and inotrope stays inotrope!
por: Luckner, Günter, et al.
Publicado: (2008)

Fibroblast growth factor 20 attenuates pathological cardiac hypertrophy by activating the SIRT1 signaling pathway
por: Chen, Yunjie, et al.
Publicado: (2022)

Circ-SIRT1 inhibits cardiac hypertrophy via activating SIRT1 to promote autophagy
por: Wang, Weichen, et al.
Publicado: (2021)

Corticosteroids reduce inotrope requirements in hypotensive liver failure
por: Harry, R, et al.
Publicado: (2001)

Inotropes do not increase mortality in advanced heart failure
por: Guglin, Maya, et al.
Publicado: (2014)

Use of Inotropic Agents in Treatment of Systolic Heart Failure
por: Tariq, Sohaib, et al.
Publicado: (2015)

Vasopressin Is No Inotrope
por: Roeleveld, Peter Paul
Publicado: (2018)

Total inotrope exposure score: an extension of the vasoactive inotrope score
por: Bangalore, H, et al.
Publicado: (2015)

MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4
por: Xiao, Yimin, et al.
Publicado: (2016)

SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury
por: Yang, Xiaoyan, et al.
Publicado: (2023)

Functions of Autophagy in Pathological Cardiac Hypertrophy
por: Li, Zhenhua, et al.
Publicado: (2015)

VCP represses pathological cardiac hypertrophy
por: Zhou, Ning, et al.
Publicado: (2017)

Effects of Widespread Inotrope Use in Acute Heart Failure Patients
por: Kang, Jeehoon, et al.
Publicado: (2018)

Long‐term administration of intravenous inotropes in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2021)

Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure
por: Forzano, Imma, et al.
Publicado: (2022)

Effects of Sirt3-autophagy and resveratrol activation on myocardial hypertrophy and energy metabolism
por: Wang, Hai-Ning, et al.
Publicado: (2020)

French multicentre survey on the use of inotropes after cardiac surgery
por: Bastien, Olivier, et al.
Publicado: (2005)

Cardiac Inotropic Effect of Long-Term Administration of Oral Thymoquinone
por: Asoom, Lubna Ibrahim Al, et al.
Publicado: (2019)

Short-term treatments for acute cardiac care: inotropes and inodilators
por: Guarracino, Fabio, et al.
Publicado: (2020)

Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3
por: Pillai, Vinodkumar B., et al.
Publicado: (2015)

Epigenetics in Cardiac Hypertrophy and Heart Failure
por: Liu, Chia-Feng, et al.
Publicado: (2019)

Deubiquitinase Ubiquitin‐Specific Protease 10 Deficiency Regulates Sirt6 signaling and Exacerbates Cardiac Hypertrophy
por: Zhang, Dian‐Hong, et al.
Publicado: (2020)

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy
por: Yang, Dan, et al.
Publicado: (2022)

Inotropes and Inodilators for Acute Heart Failure: Sarcomere Active Drugs in Focus
por: Nagy, László, et al.
Publicado: (2014)

Comparison of Positive Inotropic Agents in the Management of Acute Decompensated Heart Failure
por: Kelly, Julie, et al.
Publicado: (2020)

Threshold of Inotropic Score and Vasoactive–Inotropic Score for Predicting Mortality in Pediatric Septic Shock
por: Kallekkattu, Dipu, et al.
Publicado: (2021)

CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure
por: Zhang, Yang, et al.
Publicado: (2022)

Inotropic Effects of Trains of Impulses Applied during the Contraction of Cardiac Muscle
por: Brady, A. J., et al.
Publicado: (1960)

Inotropic and Mechanical Support of Critically Ill Patient after Cardiac Surgery
por: Keranovic, Suad, et al.
Publicado: (2020)

Differential effects of inotropes and inodilators on renal function in acute cardiac care
por: Zima, Endre, et al.
Publicado: (2020)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2016)

Novel genomic targets of valosin-containing protein in protecting pathological cardiac hypertrophy
por: Zhou, Ning, et al.
Publicado: (2020)

Retraction Statement: Effects of cardiac resynchronization therapy in patients with inotrope‐dependent class IV end‐stage heart failure
Publicado: (2019)

Glucose Metabolism in Cardiac Hypertrophy and Heart Failure
por: Tran, Diem H., et al.
Publicado: (2019)

Noncoding RNAs in Cardiac Hypertrophy and Heart Failure
por: Lu, Peilei, et al.
Publicado: (2022)

Exogenous NADPH ameliorates myocardial ischemia–reperfusion injury in rats through activating AMPK/mTOR pathway
por: Zhu, Jiang, et al.
Publicado: (2019)

Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy
por: Gomes, Clara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d4vq1fo1ognr3ccvvci6b33fe5